Retatrutide — 20mg

Retatrutide is a triple agonist peptide targeting three key metabolic receptors simultaneously — GLP-1 (glucagon-like peptide-1), GIP (glucose-dependent insulinotropic polypeptide), and glucagon. This tri-receptor activity profile makes it one of the most mechanistically complex and research-relevant peptides currently available, offering investigators a powerful tool for studying converging metabolic pathways in a single compound.

Mechanism of Interest
By engaging all three incretin and glucagon-related receptors, Retatrutide enables research into the additive and synergistic effects of combined receptor activation on energy expenditure, lipid metabolism, glucose regulation, and appetite signalling. Its glucagon receptor activity — absent in dual GLP-1/GIP agonists — adds a distinct dimension to hepatic glucose output and thermogenesis modelling.

Research Focus Areas
• Triple receptor (GLP-1 / GIP / Glucagon) agonism studies
• Energy expenditure and thermogenesis models
• Lipid metabolism and adipose tissue research
• Hepatic glucose output and insulin sensitivity
• Appetite and satiety neurological signalling
• Comparative incretin pathway research

Specifications
• Total content: 20mg
• Form: Lyophilised powder
• Purity: ≥99% — HPLC verified
• Storage: 2–8°C, away from light and moisture

———

Important Notice

This product is supplied strictly for laboratory research use only. It is not intended for human or veterinary use.

By purchasing, the buyer confirms they are a qualified professional or acting on behalf of a licensed research facility and accept full responsibility for safe handling, storage, and use in accordance with all applicable guidelines. No claims are made regarding the safety or effectiveness of this compound outside of a controlled research environment.